Methylprednisolone acetate Injectable Suspension — Class II drug recall D-0366-2024
Ongoing recall by Eugia US LLC, reported 2024-03-13, distributed in LA, MS, OH, TN. Failed Dissolution Specifications
| Recall number | D-0366-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Eugia US LLC, East Windsor, NJ, United States |
| Recall initiated | 2024-02-20 |
| Classified | 2024-03-04 |
| Reported by FDA | 2024-03-13 |
| Distributed | LA, MS, OH, TN |
| Quantity | 10,080 vials |
| Reason classes | specification failure |
| NDC | 55150-0313, 55150-0313-01, 55150-0313-25, 55150-0314, 55150-0314-01, 55150-0314-25 |
| Lot numbers | 3MA23001, 3MA23002, 3MA23003 |
| Expiration dates | 2025-03-31 |
Product
Methylprednisolone acetate Injectable Suspension, USP, 400mg per 5mL (80mg/mL, 5mL Multiple-Dose Vial, Rx only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520, NDC 55150-314-01
Reason for recall
Failed Dissolution Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0366-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.